New Insights into a Novel Metabolic Biomarker and Therapeutic Target for Chronic Kidney Disease

作者：Dan‐Qian Chen, Yan Guo, Ping Li · 发表于：Integrative Medicine in Nephrology and Andrology · 年份：2024 · DOI：10.1097/imna-d-24-00019 · 被引用次数：27 · 研究领域：Liver Disease Diagnosis and Treatment、Hormonal Regulation and Hypertension、Chronic Kidney Disease and Diabetes

Chronic kidney disease (CKD) affects approximately 13% of the global population.[1] CKD contributes to kidney dysfunction and eventually progresses to end-stage kidney disease. In its early stages, CKD is often asymptomatic, with kidney function decline and proteinuria occurring in later stages. However, once CKD advances, kidney function is significantly reduced, necessitating dialysis or a transplant.[2] This underscores the importance of an early-stage diagnosis of CKD. In clinical settings, the estimated glomerular filtration rate (eGFR) is used to distinguish the stages of CKD, which is calculated using serum creatinine. However, traditional biomarkers, such as serum creatinine and proteinuria, are susceptible to interference from non-renal processes, highlighting the urgent need for the identification of novel CKD biomarkers. The development of reliable biomarkers is crucial not only for early diagnosis but also for improving the precision of treatment strategies, potentially enhancing patient outcomes significantly. Through untargeted metabolomic approaches, primary disturbances in serum galactose metabolism and glycerolipid metabolism have been identified in patients with diabetic kidney disease (DKD).[3] Mechanistic research employing spatial metabolomics has revealed the facilitative role of endogenous adenine in DKD progression, with adenine inhibition proving effective in mitigating kidney hypertrophy and injury in DKD mice.[4] Targeted metabolomics has identified...